Inclusion Criteria:

- Capable of giving signed informed consent

- Refractory chronic cough (including unexplained chronic cough) for at least one year

- Women of child-bearing potential must use a highly effective contraception method
during the study and for at least 14 days after the last dose

Exclusion Criteria:

- Current smoker/vaper (all forms of smoking and inhaled substances, including ,
cannabis/tobacco smoke and nicotine vapors) or individuals who have given up smoking
within the past 6 months, or those with >20 pack-year smoking history

- Diagnosis of Chronic Obstructive Pulmonary Disease (COPD), bronchiectasis, idiopathic
pulmonary fibrosis or uncontrolled asthma

- Respiratory tract infection within 4 weeks before screening

- Laboratory confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
infection at screening

- History of malignancy in the last 5 years

- History of alcohol or drug abuse within the last 3 years

- Has a positive serologic test for human immunodeficiency virus (HIV), hepatitis B
virus surface antigen, or hepatitis C virus.

- Previous participation in a BLU-5937 trial

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 12/21/23. Questions regarding updates should be directed to the study team contact.